Abstract. The metabolism of arachidonic acid by either cyclooxygenase or lipoxygenase is believed to play an important role in carcinogenesis. Leukotriene (LT) D 4 is a proinflammatory mediator derived from arachidonic acid through various enzymatic steps, and 5-lipoxygenase is an important factor in generating LTD 4 . We investigated LTD 4 receptor (cysteinylLT 1 receptor; CysLT 1 R) expression in testicular cancer (TC), as well as the effects of the CysLT 1 R antagonist on cell proliferation in a TC cell line. CysLT 1 R expression in tissue from TC patients and normal testes (NTs) was detected using immunohistochemistry and RT-PCR. The effects of the CysLT 1 R antagonist on TC cell growth were examined using the MTT assay. Flow cytometry was used to determine whether or not the CysLT 1 R antagonist induces apoptosis. Immunohistochemistry indicated that CysLT 1 R expression was strong in all types of TC tissues, but very weak in NT tissues. The TC cell line expressed CysLT 1 R mRNA as detected by RT-PCR. MTT and flow cytometry revealed that the CysLT 1 R antagonist caused marked inhibition of TC cells through early apoptosis. In conclusion, CysLT 1 R was induced in TC. The results suggest that the CysLT 1 R antagonist may mediate potent antiproliferative effects against TC cells. Thus, CysLT 1 R may become a new therapeutic target for the treatment of TC.
Introduction
Testicular cancer (TC) is relatively rare, but angiogenetic factors are considered to play an important role in invasion in both TC cells and other organs. In recent years, the expression of angiogenic factors in solid human tumors has been widely reported (1) . Growth factors secreted by tumor cells, such as fibroblast growth factor and transforming growth factor, have been demonstrated to increase neovascularization in vivo and in vitro (2) .
The metabolism of arachidonic acid (AA) by either the cyclooxygenase (COX) or lipoxygenase (LOX) pathway generates eicosanoids, These have been implicated in the pathogenesis of a variety of human diseases, including cancer, and are significantly involved in tumor promotion, progression and metastasis. Studying these pathways in specimens from patients with TC, we demonstrated that COX-2 and 5-LOX were overexpressed in TC tissues (3, 4) .
Leukotriene (LT) belongs to an important group of proinflammatory mediators and is synthesized by AA via the 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable LTA 4 , which can be converted into either LTB 4 or cysteinyl (Cys)LTs (LTC 4 , LTD 4 and LTE 4 ). LTD4 is the most important component of CysLTs (CysLT 1 , CysLT 2 ), and CysLT 1 receptor (CysLT 1 R) is specific for LTD 4 (5) . CysLTs are important mediators of human bronchial asthma, and many CysLT receptor antagonists are clinically used in its treatment. A few reports have addressed the relationship between CysLT 1 R and colon cancer (6, 7) . To date, no report has addressed the relationship between CysLT 1 R and human TC. Our team has already demonstrated that 5-LOX is overexpressed in human urological cancer (4, (8) (9) (10) .
Based on these findings, the present study aimed to examine the expression of CysLT 1 R in human TC tissues in order to evaluate the inhibitory effect of the CysLT 1 R antagonist on human TC cells, and to determine whether the CysLT 1 R antagonist induces apoptosis in these cells. Reagents and materials. RPMI-1640 was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Fetal bovine serum (FBS) and a penicillin-streptomycin mixture were from Biowhittaker (Walkersville, MD, USA). Trypsin/EDTA was from Gibco-BRL (Rockville, MD, USA). Montelukast is a selective and orally active CysLT 1 R antagonist (LKT Laboratories Inc., MN, USA) with demonstrated effectiveness for treating allergic asthma and allergic rhinitis in adults and in children as young as 12 months of age (allergic asthma) and 6 months of age (allergic rhinitis) (12) .
Cell cultures. The human TC cell line NEC-8 was obtained from the Health Science Research Resources Bank (HSRRB, Osaka, Japan). Cells were grown in a culture flask (Nunc, Roskilde, Denmark) in RPMI-1640 supplemented with 10% FBS, 100 U/ml of penicillin and 100 μg/ml of streptomycin in a humidified 5% CO 2 atmosphere at 37˚C. Media were changed every 3 days and, upon reaching subconfluence, cells were separated via trypsinization using trypsin/EDTA.
Cell proliferation studies. Approximately 1.0x10 4 cells placed on 8x8-mm diameter multichamber slides (Nunc, Copenhagen, Denmark) were treated with the CysLT 1 R antagonist dissolved in ethanol at a final concentration of <0.05%. Cell viability was measured on day 1 by a microplate reader using a modified 3-[4,5-dimethylthiazol-2-thiazolyl]-2,5-diphenyltetrazolium bromide (MTT) assay (WST-1 assay; Dojindo, Kumamoto, Japan) and presented as the percentage of control-culture conditions.
RT-PCR of CysLT 1 R. Total RNA was isolated from NEC-8 cells using the RNAqueous ® Kit (Ambion, Japan) and checked for the presence of the CysLT 1 R gene using primers (sense 5'-CTGCTCGCTTCGCTACTTGGA-3', antisense 5'-CGG CACCTGTCCTACGAGTTG-3' (Takara RNA PCR™ Kit, Takara Bio, Japan). The first step of PCR was carried out for 2 min at 94˚C. Subsequent steps involved 35 cycles as follows: 30 sec at 94˚C, 45 sec at 60˚C and 60 sec at 72˚C. The presence of the CysLT 1 R gene (650 bp) was visualized on a 0.7% agarose gel. 
Flow cytometry

Results
CysLT 1 R expression in testis tissue. Very weak CysLT 1 R expression was observed in the NT case (Fig. 1F) . In contrast, significantly strong CysLT 1 R expression was observed in cancer tissues, including the nuclei and cytoplasm, in all TC types (Fig. 1A, seminoma ; B, embryonal carcinoma; C, yolk sac tumors; D, choriocarcinoma; and E, teratoma). Immunostaining with PBS was negative in all subjects (data not shown).
CysLT 1 R antagonist-induced growth inhibition in TC cells as determined by the MTT assay.
Treatment with the CysLT 1 R antagonist induced a reduction in cell viability with the halfmaximal concentration of growth inhibition of NEC-8 cells in the range of 12.5-100 μM (Fig. 2) . The CysLT 1 R antagonist halted the growth of NEC-8 cells.
CysLT 1 R expression in TC cells. Using specific primers for CysLT 1 R and GAPDH amplification predicted fragments of 650 and 400 bp. NEC-8 cells expressed CysLT 1 R mRNA bands (Fig. 3, lane 2) . CysLT 1 R mRNA bands with 100 μM CysLT 1 R antagonist in NEC-8 cells were down-regulated (Fig. 3, lane 4) . (Fig. 4A) . The CysLT 1 R antagonist (100 μM) induced DNA fragmentation in NEC-8 cells (Fig. 4B ).
Discussion
Leukotrienes (LTs) are biologically active fatty acids derived from the oxidative metabolism of arachidonic acid (AA) (13, 14) via the 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable LTA 4 , which can be converted into either LTB 4 or CysLTs (LTC 4 , LTD 4 and LTE 4 ). CysLTs are components of a slow-reacting substance of anaphylaxis. LTD 4 plays the most important role in CysLTs (CysLT 1 , CysLT 2 ), and CysLT 4 is specific for LTD 4 . LTs are potent biochemical mediators, released from mast cells, eosinophils and basophils, that work to contract airway smooth muscle, increase vascular permeability and mucus secretions, and attract and activate inflammatory cells in the airways of patients with asthma (15) . The action of LTs can be blocked through either of two specific mechanisms, i) the inhibition of LT production, and ii) the antagonism of LT binding to cellular receptors.
On the other hand, the 5-LOX inhibitor inhibits LT formation (particulary LTB 4 , LTC 4 , LTD 4 and LTE 4 ). Our previous studies reported that 5-LOX was overexpressed in urological cancers and that the 5-LOX inhibitor may attenuate the growth of human urological cancers and induce apoptosis through the AA pathway (4, (8) (9) (10) 16) . Based on these findings, we examined whether or not CysLT 1 R is expressed in human testicular cancer (TC) tissues, and whether or not it would, as an antagonist, prevent TC cell growth.
The present study revealed CysLT 1 R to be strongly expressed in TC tissue. We also found, by RT-PCR, that CysLT 1 R was expressed in the TC NEC-8 cell line. RT-PCR determined CysLT 1 R expression to be down-regulated by 100 μM CysLT 1 R antagonist.
Additionally, co-incubation of NEC-8 with CysLT 1 R antagonist was demonstrated to stop the growth of NEC-8 cells and to potently inhibit cell growth in a dose-dependent manner, determined by the MTT assay. These results indicate that CysLT 1 R is essential for the cell growth of NEC-8 cells. The mechanism by which the CysLT 1 R antagonist supressed growth in NEC-8 cells required clarification. To address this issue, we examined whether or not apoptosis was involved in growth suppression in these cancer cells. The CysLT 1 R antagonist (100 μM) strongly induced early apoptosis in NEC-8 cells, as shown by flow cytometry. Our results indicate that apoptosis may be involved in mechanisms related to the CysLT 1 R antagonist, thus preventing cell growth in NEC-8 cells. These findings therefore provide inital confirmation that, through apoptosis, the CysLT 1 R antagonist inhibits TC cell growth.
Regarding CysLT 1 R and colon cancer, Ohd et al reported that CysLT 1 R was overexpressed in human colorectal cancer and was significantly correlated with COX-2 and 5-LOX. The expression of CysLT 1 R was higher in high-grade and earlystage carcinoma, suggesting typical differences in colon cancer (6) . Furthermore, survival time was slightly shorter in patients with high-intensity CysLT 1 R staining than in those with lowintensity staining (7) . We also reported that CysLT 1 R was overexpressed in human prostate cancer and renal cell carcinoma, and that its expression was higher in high-grade compared to low-grade cancer. Furthermore, the CysLT 1 R antagonist inhibited prostate cancer and renal cell carcinoma cell growth through apoptosis (17, 18) . These reports suggest that there are numerous relationships between CysLT 1 R and various types of cancers, and that the CysLT 1 R antagonist can prevent cell growth in other types of cancer besides TC.
In conclusion, our study provides evidence that the cell growth and apoptosis of TC cells are among the pathways or mechanisms related to CysLT 1 R. Growth inhibition of TC cells by blocking CysLT 1 R was associated with the induction of apoptosis. Thus, the CysLT 1 R antagonist provides a novel approach to anticancer therapies.
